Newsroom 2014
Everything BrainStorm published in 2014.
Latest from BrainStorm
-
BrainStorm Cell Therapeutics to Host Conference Call to Discuss Final Results of Phase 2a Trial of NurOwn™ in ALS on January 5, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will release the final results from its phase 2a clinical trial of NurOwn™ in amytrophic lateral sclerosis (ALS) and hold a conference call and webcast to discuss the
-
BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant of approximately $1.1 million from Israel's Office of the Chief Sci
-
BrainStorm Announces Financial Results for the Third Quarter of 2014 and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three and nine months ending September 30, 2014.
-
BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report third quarter 2014 financial results on Thursday, November 13, 2014. The Company will issue a press release before the market opens and wi
-
FDA Grants Fast Track Designation to NurOwn™ for the Treatment of ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn™ as a Fast Track product for the treatment of amyotrophic lateral scle
-
BrainStorm Reports Last Patient Visit in Phase 2a ALS Study
BrainStorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the last patient has completed the last visit in its phase 2a clinical trial of NurOwn™ in Amyotrophic Lateral Sclerosis (ALS), conducted at the Hadas
No press releases match that search. Try a shorter phrase, or clear the field to see the full list.
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.